• Home
• About
  • About Lipaglyn
  • About Zydus
  • About ZRC
• Doctors
• Patients
• Health Blog
• FAQs
• News Room
• Updates
• Events
• Contact us

A Novel Therapy to treat Diabetic Dyslipidemia

Novel NCE from an Indian research pipeline to move from the lab to the market

A Novel Therapy to treat Diabetic Dyslipidemia

Zydus becomes the 1st Indian Pharma Company to launch an NCE

It’s first-of-its kind novel action works as a lipid regulator and also provides glycemic benefits

This marks the beginning of India’s contribution to the world of drug discovery

LIPAGLYN - The novel drug for treating Diabetic Dyslipidemia

combines lipid and glucose lowering effects in one single molecule.

Updates

Original Articles
	Observational Study To Evaluate Effect of Saroglitazar in Indian Diabetic Dyslipidemia patients
	A Prospective Multicentre Open Label Single Arm Study to Evaluate Efficacy and Safety of Saroglitazar on Hypertriglyceridemia in HIV associated Lipodystrophy
	Comparison of Effectiveness and Safety of Add-on Therapy of Saroglitazar and Fenofibrate with Metformin in Indian Patients with Diabetic Dyslipidaemia
	Observational Study of Effects of Saroglitazar on Glycaemic and Lipid Parameters on Indian Patients with Type 2 Diabetes
	Observational study to evaluate the safety and efficacy of saroglitazar in Indian diabetic dyslipidemia patients
	From ‘Make in India’ to ‘Made in India’: The saroglitazar story
	Lipaglyn Saroglitazar Phase III Press VI
	Lipaglyn Saroglitazar Phase III Press V
	Saroglitazar - Phase-I Publication    (Download)
Review Articles
	Diabetic Dyslipidemia - Role of Saroglitazar
	The nuances of atherogenic dyslipidemia in diabetes: Focus on triglycerides and current management strategies.
	Role of Glitazars in atherogenic dyslipidemia and diabetes: Two birds with one stone?
	Atherogenic dyslipidemia
	Lipaglyn - Product Information Booklet

Disclaimer : Lipaglyn is a prescription drug authorised for sale in India only and can be taken only under the advice and guidance of a registered medical practitioner.